Investment Rating - The report does not explicitly state an investment rating for the sensitive skin care market Core Insights - The sensitive skin care market is experiencing rapid growth, with increasing consumer demand driving market expansion [11] - Consumer attitudes are shifting from seeking strong efficacy to preferring gentle repair and proactive prevention, with simplified skincare and additive-free products becoming mainstream [11] - Technological innovation is fostering the development of personalized skincare solutions, enhancing product gentleness and penetration [11] Summary by Sections Research Background Assessment - The report is conducted by Zhi Yi Technology Co., Ltd. (Lian Dan Lu), a leading company in big data and AI applications in the fashion industry, known for its authoritative market insights [3][6] Scope and Boundaries Confirmation - The sensitive skin care market includes the research, production, and sales of products suitable for sensitive skin, such as facial serums, masks, and creams [8] Key Data Capture and Presentation - The global skincare market is projected to reach USD 123.6 billion by 2025, with the sensitive skin care segment estimated at USD 44 billion [13] - By 2034, the sensitive skin care market is expected to exceed USD 61 billion [13] - In China, 36% of women are reported to have sensitive skin [13] - Sales trends on major platforms indicate a fluctuating upward trend in sensitive skin care market sales, significantly influenced by promotional events [13] Challenges and Opportunities Diagnosis - The potential growth opportunity in lower-tier cities is significant due to rising consumer awareness and health consciousness [15] - The male sensitive skin market remains largely untapped, presenting considerable growth potential [17] - Personalized skincare solutions leveraging skin testing and AI data can meet diverse consumer needs [17]

Investment Rating - The report maintains an "Accumulate" rating for the company [2] Core Views - The company is benefiting from a dual-focus strategy on clients and products, leading to strong performance in the cosmetics ODM sector [8][22] - The company has successfully transitioned to focus solely on cosmetics manufacturing, shedding its previous chemical business, which has allowed for improved operational efficiency and profitability [20][22] - The cosmetics industry is entering a high-quality recovery phase, with the company positioned to capture market share as smaller competitors exit the market [41][54] Financial Data and Profit Forecast - Total revenue projections for the company are as follows: - 2024: 1,940 million CNY - 2025: 2,218 million CNY (14.3% YoY growth) - 2026: 2,565 million CNY (15.6% YoY growth) - 2027: 2,957 million CNY (15.3% YoY growth) [7] - Net profit forecasts are: - 2025: 153 million CNY (179.7% YoY growth) - 2026: 192 million CNY (25.3% YoY growth) - 2027: 242 million CNY (26.2% YoY growth) [7] - The company’s gross margin is expected to stabilize around 17.4% for the next few years, with a notable increase in 2025 to 19.2% [7][40] Business Strategy and Market Position - The company has established itself as a leading player in the global cosmetics ODM market, with significant production capacity and a diverse client base including major international brands [8][20] - The company’s focus on high-margin products, particularly in the mask and skincare segments, is expected to drive future growth [8][10] - The company has a strong R&D team and has accumulated a significant number of patents, enhancing its competitive edge in product development [8][10] Industry Outlook - The Chinese cosmetics market is projected to continue its growth trajectory, with a compound annual growth rate of 5.84% from 2015 to 2024, positioning it as the second-largest market globally [41][47] - The industry is experiencing a consolidation phase, with leading companies gaining market share as smaller players exit, which is beneficial for the company [54][56] - Consumer demand is shifting towards high-quality and effective products, which aligns with the company’s strategic focus on innovation and quality [41][47]

Sales Goals and Performance - The company has set internal sales targets for 2026, which will not be disclosed externally, and is optimistic about achieving good performance based on refined operations in 2025 [2] - The sales ratio of online to offline channels has improved from 80:20 in the 2025 semi-annual report, with further details to be revealed in the 2025 annual report [2][3] - The company reported good performance during the 3.8 promotional event, aligning with expectations, and aims to enhance sales through active participation in platform activities [3] Product Development and Innovation - The company has a robust pipeline of new products for 2026, including various forms such as dressings, masks, lotions, creams, and serums, with specifics to be confirmed based on actual launches [3] - The R&D team has expanded significantly compared to early 2025, with improvements in the educational background of its members [3] Profitability and Business Strategy - The company plans to strengthen its offline business in 2026, which has a higher net profit margin compared to online sales, and is confident in achieving better overall profitability [3] - The company is considering stock incentive plans but has not set a specific timeline for implementation, with future updates to be disclosed in accordance with regulatory requirements [3] Dividend and Financial Planning - The dividend plan for the current year has not yet been determined, and stakeholders are advised to monitor announcements scheduled for April 23, 2026 [3] General Information - The investor relations activity did not involve any major information that needs to be disclosed [3]

Group 1: Channel Optimization and Sales Outlook - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining strong offline sales efforts [3] Group 2: New Product Planning - The company has a well-prepared new product plan for 2026, covering various product forms including dressings, masks, lotions, creams, and serums, with actual launches to be confirmed later [3] Group 3: Non-Patch Product Revenue Trends - Since the establishment of the Shanghai R&D center, the company has increased its focus on non-patch products, leading to a rising revenue share from these products [3] Group 4: OTC Channel Development - The current coverage of the OTC channel is relatively low, indicating significant expansion potential; the company plans to increase personnel in this area to improve pharmacy coverage [3] Group 5: Sales Performance and Promotions - Sales during the 38 Festival are meeting expectations, with a focus on daily sales complemented by promotional activities to enhance overall performance [3] Group 6: Product Development Progress - Clinical trials for the recombinant type III humanized collagen freeze-dried fibers have been completed, with submission materials being prepared; other products are at various stages of clinical trials [3] Group 7: Shareholder and Acquisition Plans - The chairman has no current plans to reduce his shareholding, and while the company is monitoring potential acquisition targets, there are no suitable candidates at this time [3] Group 8: Dividend Considerations - The dividend proposal for the fiscal year 2025 has not yet been determined, and stakeholders are encouraged to stay updated [4]

Group 1: Sales and Market Strategy - The company's offline channel optimization is progressing as expected, focusing on "strong regulation + strong optimization" to enhance market control and balance inventory levels to avoid excess stock risks [2] - The sales outlook for 2026 will be assessed after the release of periodic reports, with the company committed to maintaining offline sales efforts [3] - The company has increased personnel in the OTC channel to improve pharmacy coverage, indicating significant growth potential in this area [3] Group 2: Product Development and Innovation - The company has a well-prepared product plan for 2026, including various new product forms such as dressings, masks, lotions, creams, and serums [3] - Since the establishment of the Shanghai R&D center, the revenue share of non-patch products has been increasing due to ongoing R&D efforts [3] - Progress on three types of medical devices includes completion of clinical trials for recombinant type III humanized collagen freeze-dried fibers and initiation of clinical trials for other products [3] Group 3: Financial and Corporate Governance - The chairman has no plans to reduce his shareholding in the company, ensuring stability in corporate governance [3] - The dividend plan for the fiscal year 2025 has not yet been determined, pending further developments [4] - The company is monitoring potential acquisition projects but currently has no suitable targets [3]

Core Viewpoint - The beauty industry is experiencing a shift towards high-quality products, but the face mask category in China has struggled to align with this trend, often being perceived as a low-cost promotional item rather than a premium product [3][4][6]. Market Trends - The Chinese face mask market is projected to reach 75.79 billion yuan by 2025, with a growth rate slowing to 9.2%. Online sales of face masks are expected to approach 30 billion yuan, with a year-on-year growth exceeding 20% [8]. - Despite the growth, the market remains dominated by mid to low-end products, with over 40% of online sales coming from masks priced below 50 yuan. The demand for high-end masks is evident but not fully realized [9][10]. Consumer Perception - Consumers associate high-end masks primarily with price, lacking a clear understanding of what constitutes a premium product. This has led to a significant gap in the perceived value of high-end masks compared to their actual market potential [10][11]. - The absence of standardized criteria for high-end masks has resulted in a lack of effective consumer recognition and differentiation, limiting the category's growth [11][14]. Research and Development - Continuous innovation in mask materials, formulations, and delivery methods is crucial for enhancing product value. The industry has yet to establish a unified understanding of the technological requirements for high-end masks [11][13]. - Companies like Beihau are leading the way in research and development, focusing on creating a comprehensive scientific framework that includes ingredient research, formulation development, and efficacy validation [13][17]. Cultural and Aesthetic Value - The integration of cultural and aesthetic dimensions into the face mask category is essential for elevating its status. Beihau aims to connect the product with broader lifestyle and emotional experiences, moving beyond mere functionality [16][18]. - The establishment of industry standards and cultural narratives around face masks can help reshape consumer perceptions and enhance the overall market value [23][24]. Industry Leadership - Beihau is positioned as a key player in driving the high-end face mask market forward, leveraging its extensive research background and commitment to quality standards [15][20]. - The company's initiatives, including the establishment of international manufacturing facilities and participation in major beauty exhibitions, aim to enhance the global presence and premium positioning of Chinese face masks [20][22].

Group 1: Sales and Marketing Strategies - The company is actively promoting its brand and products ahead of the International Women's Day sales event, aiming for strong sales performance [2] - The company plans to launch new products across various formats, including water, lotion, cream, and essence, in addition to upgrading existing products [2] Group 2: E-commerce Operations - The company has established e-commerce teams in Harbin, Shanghai, and Hangzhou, with specific teams focusing on different platforms like Douyin and Tmall [3] - The profitability of Tmall and Douyin will be assessed after the annual report, but both platforms have shown rapid growth and alignment with company expectations [3] Group 3: Product Development and Medical Devices - The company continues to develop medical devices, focusing on both Class II and Class III products, leveraging a collaborative R&D model [3] - The company aims to enhance its medical device product matrix to improve profitability [3] Group 4: Inventory and Production Management - The company follows a sales-driven production principle to manage inventory effectively, minimizing operational costs and market risks [4] - There is no significant risk of inventory backlog due to the company's efficient production planning [4] Group 5: Future Outlook and Corporate Governance - The company has plans for stock incentives, but the timing and implementation remain uncertain [4] - The chairman currently has no plans to reduce his shareholding in the company [4]

Investment Rating - The report maintains a positive outlook on the industry, indicating a "Buy" rating [11] Core Insights - The beauty industry shows stable growth, with core categories still having room for domestic market penetration. The skincare market is projected to reach CNY 271.2 billion by 2024, with a compound annual growth rate (CAGR) of 2.1% over five years [20][21] - The competitive landscape in beauty can be analyzed through product categories and channels, leading to two main conclusions: established brands with a leading advantage in categories like lotions and serums are likely to maintain their dominance, especially on platforms like Tmall, while brands seeking growth can leverage emerging channels like Douyin [4][10] Summary by Sections Overall Market - The skincare industry is experiencing stable growth, with essential categories such as cleansing, sun protection, and moisturizing products showing strong growth stability. Since 2020, the industry's growth center has shifted downward, highlighting the resilience of these essential categories [20][21] - The domestic penetration rate for face masks, toners, and sun protection has rapidly increased since 2015, while other categories like moisturizers and cleansers still have room for growth [23][26] Category Breakdown - The concentration of leading brands in major categories is increasing, with significant head concentration observed in lotions, masks, and serums. The inter-category linkage rate is improving, particularly for core categories like serums and lotions, which are central to brand strategies [8][30] - The head concentration in the Tmall channel has shown a significant upward trend since 2019, with the exception of cleansers and toners, indicating a "stronger gets stronger" phenomenon [30][65] Channel Comparison - The competitive landscape on Tmall is relatively stable, while Douyin presents structural opportunities for brands with strong operational capabilities. The concentration ratio (CR50) for core categories on Tmall has increased, indicating a stable market structure [9][10] - Brands that have established strong brand recognition in specific categories, such as Proya in lotions and serums, are likely to maintain their leading positions [9][10] Investment Recommendations - The report suggests focusing on two main investment lines: 1. For stable configurations, brands with strong recognition in core categories and a stable Tmall presence, such as Proya and Betaini, present investment opportunities [10] 2. For growth configurations, brands that continue to expand their categories and possess strong operational capabilities on Douyin, such as Shiseido, are recommended [10]

Core Insights - The health industry in Liaocheng is a key emerging sector aimed at improving public welfare and driving economic transformation, focusing on pharmaceuticals, health foods, and medical devices [1][2] Group 1: Industry Development - Liaocheng's health industry aims to transition from "single-point breakthroughs" to "cluster collaboration" and from "traditional manufacturing" to "high-end intelligent manufacturing" by 2025 [1] - The city has 52 enterprises in the health industry, with a projected output value of 11.45 billion yuan in 2025, a year-on-year increase of 9.8%, and total profits of 2.03 billion yuan, up 13.2% [1] - The East A Ejiao and Guancounty Ganoderma industry clusters have been recognized as provincial-level health industry clusters, contributing to the city's inclusion in the provincial "Top Ten Industries" reserve [1] Group 2: Brand Development - A "1+N" brand system is being established, led by a public brand to promote multiple product brands, enhancing competitiveness [2] - The "Nine Lotus Flowers Ai" brand is being developed, with over 100 products and a comprehensive service network for moxibustion therapy [2] - The "Ai·Man Water City" brand has been launched to promote the health industry and enhance overall vitality [2] Group 3: Upgrading Traditional Brands - Dong'e Ejiao holds a 45% market share in the domestic market for Ejiao blocks, with its products recognized nationally and internationally [3] - Guancounty's Ganoderma accounts for 50% of national production and 60% of trading volume, maintaining a top-three brand value for three consecutive years [3] - The local company Qu Zhongzhou Biotechnology has over 13,000 stores globally, expanding into the beauty sector [3] Group 4: Brand Integration - The integration of brand building across the supply chain is emphasized to enhance collaboration between research, production, and sales [4] - A service system for technology transfer and commercialization is being established, involving experts and research centers [4] Group 5: Service Ecosystem - A comprehensive service system is being developed to support brand growth, including financial assistance and market cultivation [6] - The establishment of 13 key industrial parks is underway to provide standardized services for brand enterprises [6] - The implementation of local food safety standards for Ganoderma is being promoted to enhance brand credibility [6] Group 6: Future Planning - Future actions will focus on enhancing brand quality, promoting industrial collaboration, and expanding the international reach of traditional Chinese medicine [7] - The "Ai·Man Water City" public brand will be prioritized, and efforts will be made to integrate into national development strategies [7] - Plans to promote traditional Chinese medicine internationally through initiatives like the "Belt and Road" strategy are in place [7]

Core Viewpoint - The article highlights the journey of a Tibetan woman, Meduo, who is transforming the traditional craft of "Ada" into a modern skincare and cosmetic brand, while also promoting local employment and cultural heritage [4][5][6]. Group 1: Company Development - Meduo aims to establish a standardized factory for "Ada" production, which will include raw material processing, product development, and packaging, thereby reducing transportation costs and ensuring product quality [4]. - The company, Tibet Dezong Zuyu Industrial Development Co., Ltd., was founded in 2016, and it has evolved from a simple product to a diverse range of skincare and cosmetic offerings [9][10]. - The "Ada" series has expanded to include skincare sets, cosmetic products, and even calligraphy ink, with annual sales steadily increasing, establishing it as a representative brand of natural beauty products in Tibet [11]. Group 2: Market Strategy - Meduo has actively engaged in product innovation, transitioning from a single paste form to a multi-product matrix that includes skincare and makeup, while maintaining the traditional production methods [10]. - The company has leveraged online platforms and local exhibitions to promote its products, achieving a 40% share of online orders, with products reaching as far as Hainan [11]. - By collaborating with local e-commerce platforms and utilizing live demonstrations, the brand has effectively communicated the cultural significance and benefits of "Ada" to a broader audience [11]. Group 3: Community Impact - Meduo has implemented a training program for local women, providing them with skills in "Ada" production and creating job opportunities, with over 630 individuals trained to date [12]. - The company has established long-term agreements with local herders for yak milk procurement, ensuring quality raw materials while sharing the benefits of the industry with the community [13]. - Meduo also supports impoverished households in the region by providing financial assistance, reflecting a commitment to social responsibility and community upliftment [13].